These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 29161698)

  • 21. Prognostic impact of circulating tumor cell apoptosis and clusters in serial blood samples from patients with metastatic breast cancer in a prospective observational cohort.
    Jansson S; Bendahl PO; Larsson AM; Aaltonen KE; Rydén L
    BMC Cancer; 2016 Jul; 16():433. PubMed ID: 27390845
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Detection of circulating cytokeratin-19 mRNA-positive cells in the blood and the mitotic index of the primary tumor have independent prognostic value in early breast cancer.
    Tryfonidis K; Kafousi M; Perraki M; Apostolaki S; Agelaki S; Georgoulias V; Stathopoulos E; Mavroudis D
    Clin Breast Cancer; 2014 Dec; 14(6):442-50. PubMed ID: 24958324
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Changes in keratin expression during metastatic progression of breast cancer: impact on the detection of circulating tumor cells.
    Joosse SA; Hannemann J; Spötter J; Bauche A; Andreas A; Müller V; Pantel K
    Clin Cancer Res; 2012 Feb; 18(4):993-1003. PubMed ID: 22228641
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The impact of HER2 phenotype of circulating tumor cells in metastatic breast cancer: a retrospective study in 107 patients.
    Wallwiener M; Hartkopf AD; Riethdorf S; Nees J; Sprick MR; Schönfisch B; Taran FA; Heil J; Sohn C; Pantel K; Trumpp A; Schneeweiss A
    BMC Cancer; 2015 May; 15():403. PubMed ID: 25972110
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Detection of EpCAM positive and negative circulating tumor cells in metastatic breast cancer patients.
    Königsberg R; Obermayr E; Bises G; Pfeiler G; Gneist M; Wrba F; de Santis M; Zeillinger R; Hudec M; Dittrich C
    Acta Oncol; 2011 Jun; 50(5):700-10. PubMed ID: 21261508
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Expression of insulin-like growth factor-1 receptor in circulating tumor cells of patients with breast cancer is associated with patient outcomes.
    Spiliotaki M; Mavroudis D; Kokotsaki M; Vetsika EK; Stoupis I; Matikas A; Kallergi G; Georgoulias V; Agelaki S
    Mol Oncol; 2018 Jan; 12(1):21-32. PubMed ID: 28766847
    [TBL] [Abstract][Full Text] [Related]  

  • 27. KRT19 and CEACAM5 mRNA-marked circulated tumor cells indicate unfavorable prognosis of breast cancer patients.
    Wang XM; Zhang Z; Pan LH; Cao XC; Xiao C
    Breast Cancer Res Treat; 2019 Apr; 174(2):375-385. PubMed ID: 30535933
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Apoptotic circulating tumor cells in early and metastatic breast cancer patients.
    Kallergi G; Konstantinidis G; Markomanolaki H; Papadaki MA; Mavroudis D; Stournaras C; Georgoulias V; Agelaki S
    Mol Cancer Ther; 2013 Sep; 12(9):1886-95. PubMed ID: 23778153
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Elimination of EGFR-expressing circulating tumor cells in patients with metastatic breast cancer treated with gefitinib.
    Kalykaki A; Agelaki S; Kallergi G; Xyrafas A; Mavroudis D; Georgoulias V
    Cancer Chemother Pharmacol; 2014 Apr; 73(4):685-93. PubMed ID: 24493157
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Detection of circulating tumor cell-specific markers in breast cancer patients using the quantitative RT-PCR assay.
    Wang HY; Ahn S; Kim S; Park S; Jung D; Park S; Han H; Sohn J; Kim S; Lee H
    Int J Clin Oncol; 2015 Oct; 20(5):878-90. PubMed ID: 25708591
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Detection of circulating tumor cells is improved by drug-induced antigen up-regulation: preclinical and clinical studies.
    Bonmassar L; Fossile E; Scoppola A; Graziani G; Prete SP; Formica V; Cappelletti D; De Vecchis L; Cardillo A; Concolino F; D'Atri S; Balduzzi A; Torino F; Caporaso P; Greiner JW; Bonmassar E; Roselli M; Aquino A
    Anticancer Res; 2010 Nov; 30(11):4721-30. PubMed ID: 21115931
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Gene profiling and circulating tumor cells as biomarker to prognostic of patients with locoregional breast cancer.
    Kuniyoshi RK; Gehrke Fde S; Alves BC; Vilas-Bôas V; Coló AE; Sousa N; Nunes J; Fonseca FL; Del Giglio A
    Tumour Biol; 2015 Sep; 36(10):8075-83. PubMed ID: 25976504
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Correlation of hormone receptor status between circulating tumor cells, primary tumor, and metastasis in breast cancer patients.
    Kalinsky K; Mayer JA; Xu X; Pham T; Wong KL; Villarin E; Pircher TJ; Brown M; Maurer MA; Bischoff FZ
    Clin Transl Oncol; 2015 Jul; 17(7):539-46. PubMed ID: 25613123
    [TBL] [Abstract][Full Text] [Related]  

  • 34. TTF-1 mRNA-positive circulating tumor cells in the peripheral blood predict poor prognosis in surgically resected non-small cell lung cancer patients.
    Yoon SO; Kim YT; Jung KC; Jeon YK; Kim BH; Kim CW
    Lung Cancer; 2011 Feb; 71(2):209-16. PubMed ID: 20471712
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Detection of circulating tumor cells and tumor stem cells in patients with breast cancer by using flow cytometry: a valuable tool for diagnosis and prognosis evaluation.
    Wang N; Shi L; Li H; Hu Y; Du W; Liu W; Zheng J; Huang S; Qu X
    Tumour Biol; 2012 Apr; 33(2):561-9. PubMed ID: 22241087
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Detection of tumor cell-specific mRNA in the peripheral blood of patients with breast cancer—evaluation of several markers with real-time reverse transcription-PCR.
    Andergassen U; Hofmann S; Kölbl AC; Schindlbeck C; Neugebauer J; Hutter S; Engelstädter V; Ilmer M; Friese K; Jeschke U
    Int J Mol Sci; 2013 Jan; 14(1):1093-104. PubMed ID: 23299436
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Filtration-based enrichment of circulating tumor cells from all prostate cancer risk groups.
    Awe JA; Saranchuk J; Drachenberg D; Mai S
    Urol Oncol; 2017 May; 35(5):300-309. PubMed ID: 28202223
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Real-time HER2 status detected on circulating tumor cells predicts different outcomes of anti-HER2 therapy in histologically HER2-positive metastatic breast cancer patients.
    Zhang S; Li L; Wang T; Bian L; Hu H; Xu C; Liu B; Liu Y; Cristofanilli M; Jiang Z
    BMC Cancer; 2016 Jul; 16():526. PubMed ID: 27456503
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Filtration based assessment of CTCs and CellSearch® based assessment are both powerful predictors of prognosis for metastatic breast cancer patients.
    Huebner H; Fasching PA; Gumbrecht W; Jud S; Rauh C; Matzas M; Paulicka P; Friedrich K; Lux MP; Volz B; Gass P; Häberle L; Meier-Stiegen F; Hartkopf A; Neubauer H; Almstedt K; Beckmann MW; Fehm TN; Ruebner M
    BMC Cancer; 2018 Feb; 18(1):204. PubMed ID: 29463222
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Variable expression levels of keratin and vimentin reveal differential EMT status of circulating tumor cells and correlation with clinical characteristics and outcome of patients with metastatic breast cancer.
    Polioudaki H; Agelaki S; Chiotaki R; Politaki E; Mavroudis D; Matikas A; Georgoulias V; Theodoropoulos PA
    BMC Cancer; 2015 May; 15():399. PubMed ID: 25962645
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.